Search

everythinglearnresearchcommunity

for

Search:↓

The user is experiencing an allergic reaction to propylene glycol in Kirkland minoxidil and is considering switching to a foam version or a low-PG minoxidil solution. They are also contemplating oral minoxidil but are concerned about its long-term safety.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The user started using topical latanoprost and dutasteride, experiencing significant hair shedding and scalp itchiness, possibly due to an allergic reaction. They are considering stopping the treatment if the shedding is linked to an allergy.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

A user ordered Alpha Plus from Anagenica, expecting it to contain specific percentages of Fin, Estradiol, Minoxidil, and CB0301. However, the received product's label showed different percentages, including a surprising 25% CB, leading the user to question its safety and accuracy.

Whey protein isolate may worsen androgenetic alopecia (AGA) due to its potential to increase DHT levels, but finasteride use has helped maintain hair. Some users suggest avoiding protein supplements due to possible contaminants and additives that could affect hair health.

A user experienced an allergic reaction, including swollen lymph nodes, to Minoxidil 5% with an aqueous base. Switching to a non-alcohol-based Minoxidil (Prolox 5%) resolved the allergies.

The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

The conversation discusses using 1% cetirizine, an antihistamine, as a potential treatment for androgenetic alopecia (hair loss). One user plans to try cetirizine instead of finasteride, while others are curious or skeptical about its effectiveness, discussing the role of inflammation in hair loss.

The conversation is about concerns regarding starting finasteride for AGA, with a preference for topical finasteride due to worries about oral side effects. The user is considering adding oral minoxidil later due to an allergy to topical minoxidil.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

The user experienced side effects from RU58841, including dry eyes and potential eyesight issues, and decided to stop using it. They confirmed the product's legitimacy but advised caution due to its experimental status and lack of safety data.

CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.

The user is allergic to minoxidil and experienced severe itching and redness. They are considering alternatives like finasteride, dutasteride, and dermarolling for hair loss treatment.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

The conversation discusses creating a DIY topical finasteride solution for someone allergic to propylene glycol, with suggestions to use glycerin or a glycerol-based vehicle instead. The user also mentions using foam minoxidil.

The conversation discusses the potential of topical cetirizine (Zyrtec) for hair growth in comparison to minoxidil, noting cetirizine's ability to reduce prostaglandin D2, which inhibits hair growth. Users share mixed experiences with cetirizine for allergies and scalp health, and there's a mention of the risk of dementia with long-term antihistamine use.

A user experienced a painful rash from both liquid and foam minoxidil, suggesting an allergy to minoxidil itself. They are seeking others with similar experiences.

Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.

The user experienced severe hair loss, itchy scalp, and skin issues after trying no-shampoo, and wonders if it's male pattern baldness or an immune issue. They have a history of eczema, dermatitis, and jock itch, and have tried various treatments like coconut oil, peppermint, pumpkin seed, and onion.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.

There are no tests to determine genetic follicle sensitivity for hair loss, and conclusions are based on hypothetical or post-balding observations. Finasteride is mentioned as an easy, consistent treatment option compared to natural treatments.

RU58841 from rudirect caused more hair shedding and itch, while anageninc's RU58841 improved the situation. Users are concerned about the quality and authenticity of RU58841 from different suppliers, including those from China.

Hair loss discussion includes potential HMI-115 treatment. Topical mucuna pruriens shows good results, blocking prolactin possibly more important than blocking DHT.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.